.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Mallinckrodt
Federal Trade Commission
Cantor Fitzgerald
Merck
Express Scripts
Argus Health
Johnson and Johnson
Daiichi Sankyo

Generated: November 24, 2017

DrugPatentWatch Database Preview

Aprecia Pharms Co Company Profile

« Back to Dashboard

What is the competitive landscape for APRECIA PHARMS CO, and when can generic versions of APRECIA PHARMS CO drugs launch?

APRECIA PHARMS CO has one approved drug.

There are four US patents protecting APRECIA PHARMS CO drugs.

There are twenty-eight patent family members on APRECIA PHARMS CO drugs in eleven countries and two supplementary protection certificates in two countries.

Summary for Aprecia Pharms Co

International Patents:28
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-003Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-001Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-001Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-002Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-003Jul 31, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-004Jul 31, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-001Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-002Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-004Jul 31, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-004Jul 31, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Aprecia Pharms Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,114,072Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Aprecia Pharms Co Drugs

Country Document Number Estimated Expiration
Canada2906029► Subscribe
World Intellectual Property Organization (WIPO)2014144512► Subscribe
Germany69840495► Subscribe
Japan2016514680► Subscribe
European Patent Office1301177► Subscribe
Japan2017071626► Subscribe
Japan2001512488► Subscribe
Australia7368701► Subscribe
World Intellectual Property Organization (WIPO)9836738► Subscribe
Mexico2015012134► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Aprecia Pharms Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00028Netherlands► SubscribePRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
00C/032Belgium► SubscribePRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cipla
Fuji
Boehringer Ingelheim
Dow
Mallinckrodt
Chinese Patent Office
US Army
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot